The human antibody response to the influenza virus neuraminidase following infection or vaccination

Madhusudan Rajendran, Florian Krammer, Meagan McMahon

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations

Abstract

The influenza virus neuraminidase (NA) is primarily involved in the release of progeny viruses from infected cells—a critical role for virus replication. Compared to the immuno-dominant hemagglutinin, there are fewer NA subtypes, and NA experiences a slower rate of antigenic drift and reduced immune selection pressure. Furthermore, NA inhibiting antibodies prevent viral egress, thus preventing viral spread. Anti-NA immunity can lessen disease severity, reduce viral shedding, and decrease viral lung titers in humans and various animal models. As a result, there has been a concerted effort to investigate the possibilities of incorporating immunogenic forms of NA as a vaccine antigen in future vaccine formulations. In this review, we discuss NA-based immunity and describe several human NA-specific monoclonal antibodies (mAbs) that have a broad range of protection. We also review vaccine platforms that are investigating NA antigens in pre-clinical models and their potential use for next-generation influenza virus vaccines. The evidence presented here supports the inclusion of immunogenic NA in future influenza virus vaccines.

Original languageEnglish
Article number846
JournalVaccines
Volume9
Issue number8
DOIs
StatePublished - Aug 2021

Keywords

  • Antibodies
  • Influenza
  • Neuraminidase

Fingerprint

Dive into the research topics of 'The human antibody response to the influenza virus neuraminidase following infection or vaccination'. Together they form a unique fingerprint.

Cite this